Switzerland-based Roche's lung cancer drug Tecentriq (atezolizumab) has improved overall survival rate in a phase III IMpower110 study, it was reported yesterday.
The trial is assessing the product as a first-line (initial) monotherapy compared against cisplatin or carboplatin and pemetrexed or gemcitabine (chemotherapy) in advanced non-squamous and squamous non-small cell lung cancer without ALK or EGFR mutations (Wild-Type or WT).
The company's phase III trial achieved its primary endpoint in an interim analysis demonstrating that Tecentriq monotherapy had a statistically significant overall survival benefit in people with high PD-L1 expression (TC3/IC3-WT) compared against chemotherapy alone.
The firm will share the positive data with global health authorities such as the US Food and Drug Administration and European Medicines Agency to offer the new drug option to patients.
The product is a monoclonal antibody developed to bind with PD-L1 protein that is expressed on tumour cells and tumour-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors. It will allow the activation of T cells by inhibiting PD-L1.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients